# US 2020/0402634 A1 · Dynamic equivalent on board estimator

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0402634 A1
- Document ID: US20200402634A1
- Status: Published application
- Kind: A1
- Application number: 16/907,037
- Filed: 2020-06-19
- Published: 2020-12-24
- Earliest claimed: 2019-06-19
- Assignees: DexCom, Inc.
- Applicants: DexCom, Inc.
- Inventors: Stephen D. Patek; Enrique Campos-Náñez
- Web page: https://patentgrep.com/patent/US20200402634A1

## CPC

- G16H 20/17: delivered via infusion or injection
- G06N 5/04: Inference or reasoning models
- G16H 10/60: for patient-specific data, e.g. for electronic patient records
- G16H 20/10: relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H 20/30: relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
- G16H 20/60: relating to nutrition control, e.g. diets
- G16H 40/67: for remote operation
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- G16H 50/30: for calculating health indices; for individual health risk assessment
- G16H 50/50: for simulation or modelling of medical disorders
- G16H 50/70: for mining of medical data, e.g. analysing previous cases of other patients
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G06N: COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS

## Abstract

Adaptive on board estimation of exogenous pharmacon responsive to transient (i.e., impermanent) physiological effects is provided. Dynamically estimating an equivalent amount of an exogenous pharmacon on board (XOB), such as insulin and/or carbohydrates, left in the subject, is based on predictions of glucose time-series data. These estimated values, such as insulin on board (JOB), are useful for diabetes management software, including decision support and/or artificial pancreas (AP) algorithms, for example.

## Claims

### Claim 1

A method comprising:
receiving exogenous pharmacon data for a time T1, and glucose time-series data for a time period preceding a time T2 of on board estimation of the pharmacon;
estimating baseline glucose time-series data from the time T2 of XOB estimation into a time T3 based on the data for time T1 and continuous glucose monitoring (CGM) system data for the time period preceding T2;
iteratively estimating a plurality of glucose time-series data from the time T2 to the time T3 based on a range of possible values for the data at the time T2 and the CGM data for the time period preceding T2;
comparing the baseline glucose time-series data with the plurality of glucose time-series to determine a best match from which an exogenous pharmacon on board (XOB) estimate is selected; and
outputting the XOB estimate.

### Claim 2 (depends on 1)

The method of claim 1, wherein the exogenous pharmacon data is received from one of a subject or a connected device.

### Claim 3 (depends on 2)

The method of claim 2, wherein the connected device is an insulin pump.

### Claim 4 (depends on 1)

The method of claim 1, wherein the exogenous pharmacon data comprises at least one of insulin on board (JOB) or carbohydrates on board (COB).

### Claim 5 (depends on 1)

The method of claim 1, further comprising removing at least one of non-reliable data or spurious data from the exogenous pharmacon data and the glucose time-series data.

### Claim 6 (depends on 1)

The method of claim 1, wherein at least one of the exogenous pharmacon data or the glucose time-series data comprises one or more of doses or amounts of previously injected or ingested pharmacon data.

### Claim 7 (depends on 1)

The method of claim 1, wherein the glucose time-series data is continuous or semi-continuous.

### Claim 8 (depends on 1)

The method of claim 1, wherein the iteratively estimating ranges from the pharmacon being removed from 0 to the pharmacon having the full amount.

### Claim 9 (depends on 1)

The method of claim 1, wherein outputting the XOB estimate comprises outputting the XOB estimate to at least one of a diabetes management system, a diabetes management algorithm, a user interface, a bolus calculator, or an artificial pancreas (AP) system.

### Claim 10 (depends on 1)

The method of claim 1, wherein the XOB estimate comprises the equivalent amount of a pharmacon left in a subject, wherein the pharmacon comprises at least one of insulin or carbohydrates.

### Claim 11

A method comprising:
receiving insulin data for a time T1, and continuous glucose monitoring (CGM) system time-series data for a time period preceding a time T2 of insulin on board (JOB) estimation;
estimating baseline glucose time-series data from the time T2 of IOB estimation into a time T3 based on the insulin data for time T1 and CGM system data for the time period preceding T2;
iteratively estimating a plurality of glucose time-series data from the time T2 to the time T3 based on a range of possible values for the insulin data at the time T2 and the CGM data for the time period preceding T2;
comparing the baseline glucose time-series data with the plurality of glucose time-series to determine a best match from which an IOB estimate is selected; and
outputting the IOB estimate.

### Claim 12 (depends on 11)

The method of claim 11, wherein the insulin data is received from one of a subject or a connected device.

### Claim 13 (depends on 12)

The method of claim 12, wherein the connected device is an insulin pump.

### Claim 14 (depends on 11)

The method of claim 11, further comprising removing at least one of non-reliable data or spurious data from the insulin data and the CGM system time-series data.

### Claim 15 (depends on 11)

The method of claim 11, wherein at least one of the insulin data or the CGM system time-series data comprises one or more of doses or amounts of previously injected or ingested insulin data.

### Claim 16 (depends on 11)

The method of claim 11, wherein the CGM system time-series data is continuous or semi-continuous.

### Claim 17 (depends on 11)

The method of claim 11, wherein the iteratively estimating ranges from the insulin being removed from 0 to the insulin having the full amount.

### Claim 18 (depends on 11)

The method of claim 11, wherein outputting the IOB estimate comprises outputting the IOB estimate to at least one of a diabetes management system, a diabetes management algorithm, a user interface, a bolus calculator, or an artificial pancreas (AP) system.

### Claim 19 (depends on 11)

The method of claim 11, wherein the IOB estimate comprises the equivalent amount of insulin left in a subject.

### Claim 20

A method comprising:
receiving carbohydrate data for a time T1, and continuous glucose monitoring (CGM) system time-series data for a time period preceding a time T2 of carbohydrates on board (COB) estimation;
estimating baseline glucose time-series data from the time T2 of COB estimation into a time T3 based on the carbohydrate data for time T1 and CGM system data for the time period preceding T2;
iteratively estimating a plurality of glucose time-series data from the time T2 to the time T3 based on a range of possible values for the carbohydrate data at the time T2 and the CGM data for the time period preceding T2;
comparing the baseline glucose time-series data with the plurality of glucose time-series to determine a best match from which a COB estimate is selected; and
outputting the COB estimate.

### Claim 21 (depends on 20)

The method of claim 20, wherein the carbohydrate data is received from one of a subject or a connected device.

### Claim 22 (depends on 21)

The method of claim 21, wherein the connected device is a glucose monitor.

### Claim 23 (depends on 20)

The method of claim 20, further comprising removing at least one of non-reliable data or spurious data from the carbohydrate data and the CGM system time-series data.

### Claim 24 (depends on 20)

The method of claim 20, wherein at least one of the carbohydrate data or the CGM system time-series data comprises one or more of doses or amounts of previously injected or ingested carbohydrate data.

### Claim 25 (depends on 20)

The method of claim 20, wherein the CGM system time-series data is continuous or semi-continuous.

### Claim 26 (depends on 20)

The method of claim 20, wherein the iteratively estimating ranges from the carbohydrates being removed from 0 to the carbohydrates having the full amount.

### Claim 27 (depends on 20)

The method of claim 20, wherein outputting the COB estimate comprises outputting the COB estimate to at least one of a diabetes management system, a diabetes management algorithm, a user interface, a bolus calculator, or an artificial pancreas (AP) system.

### Claim 28 (depends on 20)

The method of claim 20, wherein the COB estimate comprises the equivalent amount of carbohydrate left in a subject.
